On the contrary, the use of improved Ads [174] with a leiomyoma-specific expression of critical therapeutic genes, such as DNER [176] and HSV1-TK [5], appear quite promising and present good candidates for human clinical trials. This evidence concerns the gene TKT and leiomyoma.